2013年湖北省肿瘤登记地区恶性肿瘤发病与死亡分析
|
摘要
目的分析2013年湖北省肿瘤登记地区恶性肿瘤的发病与死亡情况。方法收集2013年湖北省9个肿瘤登记处上报的恶性肿瘤发病与死亡数据以及人口资料,并用相关工具对数据进行审核与质量评估。各项质量评价指标均按国家标准纳入。结果 2013年,湖北省9个肿瘤登记地区新发病例数29 738例,发病率为284.85/10万,中标率为188.08/10万,世标率为203.59/10万。肺癌、消化系统肿瘤乳腺癌的发病率和死亡率均居前列。2013年,湖北省肿瘤登记地区恶性肿瘤死亡病例数17 986例,死亡率172.28/10万,中标率和世标率分别为107.97/10万和122.54/10万。男性发病率与死亡率均高于女性,城市地区发病率与死亡率均高于农村地区。结论 2013年湖北省肿瘤登记地区恶性肿瘤发病中标率较2012年略下降,死亡率略低于全国水平。肺癌、消化系统恶性肿瘤(肝癌、胃癌、食管癌、结直肠癌)以及乳腺癌是湖北省肿瘤防治工作的重点癌种,需重点针对这些癌种加强居民防癌核心知识的健康教育。
Objective To analyze the cancer incidence and mortality in cancer registration areas in Hubei Province in 2013. Methods The incidence, mortality and population data were collected and evaluated from nine cancer registries of Hubei Province, 2013. All quality indicators were evaluated according to national standards. Results The total estimates of new cancer cases and deaths were 29 738 and 17 986 in 2013. The crude incidence, age-standardized incidence rates by Chinese standard population(ASR China 2000) and world standard population(ASR World 2000) were 284.85/105, 188.08/105 and 203.59/105, respectively. The crude mortality, age-standardized mortality rates by ASR China 2000 and ASR World 2000 were 172.28/105,107.97/105 and 122.54/105, respectively. Lung cancer was the most common cancer and the leading cause of cancer deaths. The incidence rate and mortality of male were higher than those of female. And the incidence rate and mortality in urban areas were higher than those in rural areas. Conclusion Agestandardized incidence rate by ASR China 2000 is slightly lower than that in 2012 in cancer registration areas in Hubei Province, and the mortality is slightly lower than national rate. Lung cancer, digestive system malignancies and breast cancer are the main cancers that should be focused on the prevention and control, in terms of health education in general population.
Objective To analyze the cancer incidence and mortality in cancer registration areas in Hubei Province in 2013. Methods The incidence, mortality and population data were collected and evaluated from nine cancer registries of Hubei Province, 2013. All quality indicators were evaluated according to national standards. Results The total estimates of new cancer cases and deaths were 29 738 and 17 986 in 2013. The crude incidence, age-standardized incidence rates by Chinese standard population(ASR China 2000) and world standard population(ASR World 2000) were 284.85/105, 188.08/105 and 203.59/105, respectively. The crude mortality, age-standardized mortality rates by ASR China 2000 and ASR World 2000 were 172.28/105,107.97/105 and 122.54/105, respectively. Lung cancer was the most common cancer and the leading cause of cancer deaths. The incidence rate and mortality of male were higher than those of female. And the incidence rate and mortality in urban areas were higher than those in rural areas. Conclusion Agestandardized incidence rate by ASR China 2000 is slightly lower than that in 2012 in cancer registration areas in Hubei Province, and the mortality is slightly lower than national rate. Lung cancer, digestive system malignancies and breast cancer are the main cancers that should be focused on the prevention and control, in terms of health education in general population.
引文
[1]魏少忠,李广灿.2015湖北省肿瘤登记年报[M].武汉:湖北科学技术出版社,2016:1.[Wei SZ,Li GC.Hubei cancer registry annual report(2015)[M].Wuhan:Hubei Science&Technology Press,2016:1.]
[2]Torre LA,Rebecca F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]International agency for research on cancer.GLOBOCAN 2012:estimated cancer incidence,mortality and prevalence worldwide in 2012[EB/OL].http://globocan.iarc fr/Default.aspx,2014-08-31.
[4]庹吉妤,张敏,常江,等.2012年湖北省肿瘤登记地区恶性肿瘤发病与死亡情况分析[J].肿瘤防治研究,2016,43(11):974-9.[Tuo JY,Zhang M,Chang J,et al.Analysis of cancer incidence and mortality in Hubei cancer registries,2012[J].Zhong Liu Fang Zhi Yan Jiu,2016,43(11):974-9.]
[5]陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.[Chen WQ,Zheng RS,Zhang SW,et al.Report of cancer incidence and mortality in China,2013[J].Zhongguo Zhong Liu,2017,26(1):1-7.]
[6]赫捷,陈万青.2016中国肿瘤登记年报[M].第1版.北京:清华大学出版社,2017:61-9.[He J,Chen WQ.Chinese Cancer Registry Annual Report(2016)[M].1st ed.Beijing:Tsinghua University Press,2017:61-9.]
[7]李辉章,杜灵彬,朱陈,等.2013年浙江省肿瘤登记地区恶性肿瘤发病与死亡分析[J].中国肿瘤,2017,26(1):8-17.[Li HZ,Du LB,Zhu C,et al.Analysis of cancer incidence and mortality in Zhejiang cancer registries,2013[J].Zhongguo Zhong Liu,2017,26(1):8-17.]
[8]杨文广,汪海滔,牛雪花,等,晚期血吸虫肝硬化并发肝癌的临床及CT影像特征[J].临床荟萃,2013,28(8):923-4.[Yang WG,Jiang HT,Niu XH,et al.Late clinical and CT imaging features of schistosoma cirrhosis complicated with liver cancer[J].Lin Chuang Hui Cui,2013,28(8):923-4.
[2]Torre LA,Rebecca F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]International agency for research on cancer.GLOBOCAN 2012:estimated cancer incidence,mortality and prevalence worldwide in 2012[EB/OL].http://globocan.iarc fr/Default.aspx,2014-08-31.
[4]庹吉妤,张敏,常江,等.2012年湖北省肿瘤登记地区恶性肿瘤发病与死亡情况分析[J].肿瘤防治研究,2016,43(11):974-9.[Tuo JY,Zhang M,Chang J,et al.Analysis of cancer incidence and mortality in Hubei cancer registries,2012[J].Zhong Liu Fang Zhi Yan Jiu,2016,43(11):974-9.]
[5]陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.[Chen WQ,Zheng RS,Zhang SW,et al.Report of cancer incidence and mortality in China,2013[J].Zhongguo Zhong Liu,2017,26(1):1-7.]
[6]赫捷,陈万青.2016中国肿瘤登记年报[M].第1版.北京:清华大学出版社,2017:61-9.[He J,Chen WQ.Chinese Cancer Registry Annual Report(2016)[M].1st ed.Beijing:Tsinghua University Press,2017:61-9.]
[7]李辉章,杜灵彬,朱陈,等.2013年浙江省肿瘤登记地区恶性肿瘤发病与死亡分析[J].中国肿瘤,2017,26(1):8-17.[Li HZ,Du LB,Zhu C,et al.Analysis of cancer incidence and mortality in Zhejiang cancer registries,2013[J].Zhongguo Zhong Liu,2017,26(1):8-17.]
[8]杨文广,汪海滔,牛雪花,等,晚期血吸虫肝硬化并发肝癌的临床及CT影像特征[J].临床荟萃,2013,28(8):923-4.[Yang WG,Jiang HT,Niu XH,et al.Late clinical and CT imaging features of schistosoma cirrhosis complicated with liver cancer[J].Lin Chuang Hui Cui,2013,28(8):923-4.